Kirkland Represents Teva In $5B Ratiopharm Deal
In a move designed to help drive its growth in key European markets, Teva Pharmaceutical Industries Ltd. has agreed to fork over $4.93 billion to acquire Ratiopharm GmbH, Germany's second-largest generics...To view the full article, register now.
Already a subscriber? Click here to view full article